SINGAPORE (Oct 19): OCBC has raised its fair value estimate on Biosensors International and maintained its “hold” recommendation after the company says that a clinical trial of its stent demonstrated “superior safety and efficacy”.

The research suggests that Biosensors’ product BioFreedom has the potential to benefit patients who are at high risk of bleeding and unable to tolerate a prolonged course of dual antiplatelet therapy.

"We understand that this targeted patient group is currently not well served," OCBC says.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook